Share ownership Lonza Group AG

LONN

CH0013841017

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 05:45:05 21/01/2026 pm IST			5-day change	1st Jan Change
549.60 ^CHF	+1.10%		-1.51%	+2.19%

14/01	Lonza Group AG Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM
18/12	Swiss trade surplus at CHF 3.841 bln in November	RE

Share class: Lonza Group AG

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	7,22,26,184	6,77,92,675 ( 93.86 %)	37,48,735 ( 5.19 %)	93.86 %

Major shareholders: Lonza Group AG

Name	Equities	%	Valuation
Norges Bank Investment Management 3.085 %	21,66,785	3.085 %	1 473 M CHF
LONZA GROUP AG 3.075 %	21,59,562	3.075 %	1 468 M CHF
Nordea Investment Management AB 0.287 %	2,01,555	0.287 %	137 M CHF
Rathbones Asset Management Ltd. 0.2812 %	1,97,460	0.2812 %	134 M CHF
Capfi Delen Asset Management NV 0.2227 %	1,56,401	0.2227 %	106 M CHF
Eurizon Capital SGR SpA 0.2066 %	1,45,102	0.2066 %	99 M CHF
Sjunde AP-fonden 0.2056 %	1,44,372	0.2056 %	98 M CHF
State Street Global Advisors Ltd. 0.1519 %	1,06,672	0.1519 %	73 M CHF
Caixabank Asset Management SGIIC SA 0.1468 %	1,03,067	0.1468 %	70 M CHF
Banque Cantonale de Genève (Investment Management) 0.1463 %	1,02,750	0.1463 %	70 M CHF
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
SBI Funds Management Ltd. 0.0342 %	2,40,000	0.0342 %	16 M CHF
Azimuth Capital Investment Management LLC 0.0199 %	1,39,435	0.0199 %	9 M CHF
Zevin Asset Management LLC 0.0187 %	1,31,336	0.0187 %	9 M CHF
Torray Investment Partners LLC 0.0138 %	97,095	0.0138 %	7 M CHF
Domini Impact Investments LLC 0.003517 %	24,700	0.003517 %	2 M CHF
Madison Asset Management LLC 0.003122 %	21,926	0.003122 %	1 M CHF
Hantz Financial Services, Inc. 0.002396 %	16,825	0.002396 %	1 M CHF
RhumbLine Advisers LP 0.002088 %	14,666	0.002088 %	995 572 CHF
Henry James International Management, Inc. 0.001058 %	7,427	0.001058 %	504 167 CHF
Accent Capital Management LLC 0.000058 %	408	0.000058 %	27 696 CHF
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	8.81%
Lonza Group AG	3.08%
Individuals	0.05%
Unknown	88.06%

Based on 1000 largest holdings

Geographical origin of shareholders

Switzerland	4.66%
Norway	3.14%
United States	0.69%
United Kingdom	0.58%
Sweden	0.49%
India	0.34%
Italy	0.34%
Germany	0.24%
Belgium	0.24%
France	0.19%
Spain	0.18%
Ireland	0.16%
Luxembourg	0.16%
Canada	0.11%
Netherlands	0.08%
Liechtenstein	0.07%
Individuals	0.05%
Finland	0.05%
Austria	0.04%
Hong Kong	0.03%
Japan	0.02%
Denmark	0.02%
Malaysia	0.01%
Slovenia	0.01%
Taiwan	0.01%
South Africa	0.01%
Australia	0.01%

Based on 1000 largest holdings

Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (57.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (16.5%). In addition, the group offers nutritional ingredients; - small molecule drug substances (15.3%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (10.8%).

Employees

19,299

Sector

Biotechnology & Medical Research

Calendar

28/01 - Q4 2025 Earnings Release

More about the company